Literature DB >> 10742311

Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells.

T Yoshioka1, N Iwamoto, F Tsukahara, K Irie, I Urakawa, T Muraki.   

Abstract

1. Carvedilol, an adrenoceptor blocker with antioxidant activity, was studied for its ability to interact with NO in a cell-free condition and in an endothelial cell line (ECV304). 2. In a cell-free system, carvedilol attenuated NO-dependent reduction of carboxy-2-phenyl-4,4, 5,5-tetramethyl-imidazoline-1-oxyl-3-oxide induced by a NO donor, 1-hydroxy-2-oxo-3-(aminopropyl)-3-isopropyl-1-triazene (NOC5), which was determined by electron paramagnetic resonance (EPR) spectrometry. The EPR study also showed that nitrosylhaemoglobin formation in rat red blood cells by the addition of NO-saturated solution was attenuated by prior incubation with 0.1 - 10 microM carvedilol. 3. NO-induced fluorescence in 4,5-diaminofluorescein-2 diacethyl (DAF-2DA)-loaded ECV304 cells was attenuated by carvedilol but not by labetalol. The IC(50) of carvedilol for NOC5 or sodium nitroprusside-induced fluorescence of DAF-2DA in ECV304 cells was 1. 0x10(-7) M, which was similar to the reported IC(50) of carvedilol for the antioxidant effect. 4. Cell toxicity induced by a NO donor determined by the number of viable cells after 24 h treatment with 2-2'(hydroxynitrosohydrazino)bis-ethanamine was significantly attenuated by pretreatment with 1 microM carvedilol. 5. Both free and cell-associated carvedilol quenched NO. Because NO mediates both physiological and pathophysiological processes, NO quenching by the drug may have diverse clinical implications depending upon specific functions of local NO in tissues where carvedilol is distributed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742311      PMCID: PMC1571989          DOI: 10.1038/sj.bjp.0703241

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  The potential clinical impact of 20 years of nitric oxide research.

Authors:  R A Cohen
Journal:  Am J Physiol       Date:  1999-04

2.  Spontaneous transformation and immortalization of human endothelial cells.

Authors:  K Takahashi; Y Sawasaki; J Hata; K Mukai; T Goto
Journal:  In Vitro Cell Dev Biol       Date:  1990-03

3.  A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts.

Authors:  J H Kramer; W B Weglicki
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

4.  Enzyme-independent formation of nitric oxide in biological tissues.

Authors:  J L Zweier; P Wang; A Samouilov; P Kuppusamy
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

Review 5.  EPR characterization of molecular targets for NO in mammalian cells and organelles.

Authors:  Y Henry; M Lepoivre; J C Drapier; C Ducrocq; J L Boucher; A Guissani
Journal:  FASEB J       Date:  1993-09       Impact factor: 5.191

6.  A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay.

Authors:  S A Ahmed; R M Gogal; J E Walsh
Journal:  J Immunol Methods       Date:  1994-04-15       Impact factor: 2.303

7.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.

Authors:  T L Yue; H Y Cheng; P G Lysko; P J McKenna; R Feuerstein; J L Gu; K A Lysko; L L Davis; G Feuerstein
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

8.  Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction.

Authors:  T Akaike; M Yoshida; Y Miyamoto; K Sato; M Kohno; K Sasamoto; K Miyazaki; S Ueda; H Maeda
Journal:  Biochemistry       Date:  1993-01-26       Impact factor: 3.162

9.  An application of electron paramagnetic resonance to evaluate nitric oxide and its quenchers.

Authors:  T Yoshioka; N Iwamoto; K Ito
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  8 in total

Review 1.  The latest generation of beta-blockers: new pharmacologic properties.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

2.  Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy.

Authors:  Kenji Nishioka; Keigo Nakagawa; Takashi Umemura; Daisuke Jitsuiki; Keiko Ueda; Chikara Goto; Kazuaki Chayama; Masao Yoshizumi; Yukihito Higashi
Journal:  Heart       Date:  2007-02       Impact factor: 5.994

Review 3.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

4.  Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: involvement of Akt and Nrf2/ARE pathways.

Authors:  Lan Wang; Rikang Wang; Minghua Jin; Yingjuan Huang; Anmin Liu; Jian Qin; Meihui Chen; Shijun Wen; Rongbiao Pi; Wei Shen
Journal:  Neurochem Res       Date:  2014-06-21       Impact factor: 3.996

5.  Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 6.  Advances in pharmacologic modulation of nitric oxide in hypertension.

Authors:  Yoshiko Mizuno; Robert F Jacob; R Preston Mason
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

7.  Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice.

Authors:  Anil Kumar; Samrita Dogra; Atish Prakash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-15       Impact factor: 3.000

Review 8.  Targeting nitric oxide with drug therapy.

Authors:  R Preston Mason; John R Cockcroft
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.